Cancerify Logo
Log inSign up
Back to clinical trials
RecruitingInterventionalPhase 2

A Phase II, Randomized, Open-label, Multi-center Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

NCT ID: NCT06991556Sponsor: Novartis PharmaceuticalsLast updated: 2026-06-10

Summary

This Phase II study aims to evaluate efficacy and safety of the combination of JSB462 (also known as luxdegalutamide) at 100 mg and 300 mg once a day (QD) doses + abiraterone compared with an androgen receptor pathway inhibitor (ARPI, abiraterone or enzalutamide) in participants with metastatic Hormone Sensitive Prostate Cancer (mHSPC) and to select the recommended dose of the combination for phase III. Towards that end, the totality of the efficacy, safety, tolerability and PK data from participants randomized in the study will be evaluated

Detailed description

The study for each participant consists of a Screening period (28 days), a treatment period, a post-treatment safety follow-up (30 days) followed by a long-term follow-up period. During the treatment period: * JSB462 is administered from randomization, orally, daily and continuously (100 mg or 300 mg QD) until disease progression per PCWG3-modified RECIST 1.1 as assessed by the investigator, the occurrence of unacceptable toxicities, death, participant decision or investigator decision. * Abiraterone 1000 mg or enzalutamide 160 mg are administered from randomization, orally, daily, and continuously until disease progression per PCWG3-modified RECIST 1.1 as assessed by the investigator, the occurrence of unacceptable toxicities, death, participant decision or investigator decision. During the post-treatment follow up period: * Safety follow-Up: After discontinuation of study treatment, all participants will be followed for at least 1 safety follow-up visit (30 days \[+/- 7 days\] after treatment discontinuation). Subsequent lines of therapy may be administered according to investigator's discretion after treatment discontinuation. * Long-term follow-up: Starts after the Safety follow-up period and lasts until the end of study. Safety, efficacy and survival information may be collected from participants during this period.

Arms & interventions

  • DrugJSB462

    JSB462 is administered orally, daily and continuously (100 mg or 300 mg QD) until disease progression per PCWG3-modified RECIST 1.1 as assessed by the investigator, the occurrence of unacceptable toxicities, death, participant decision or investigator decision.

  • DrugAbiraterone

    Abiraterone 1000 mg is administered orally, daily and continuously until disease progression per PCWG3-modified RECIST 1.1 as assessed by the investigator, the occurrence of unacceptable toxicities, death, participant decision or investigator decision.

  • DrugEnzalutamide

    Enzalutamide 160 mg is administered orally, daily and continuously until disease progression per PCWG3-modified RECIST 1.1 as assessed by the investigator, the occurrence of unacceptable toxicities, death, participant decision or investigator decision.

Outcome measures

Primary

  • Prostate Specific Antigen 90 (PSA90) Rate

    Prostate Specific Antigen 90 (PSA90) Rate is defined as the proportion of participants who achieve a ≥90% decrease in PSA from baseline at any timepoint, confirmed by a second PSA measurement ≥3 weeks without any PSA progression in between.

    Time frame: From date of randomization till 30 days safety fup, assessed up to approximately 75 months

  • Incidence rate of adverse events (AEs)

    The analysis of adverse events will include categorization by type, frequency, and severity, as graded by the NCI CTCAE version 5.0.

    Time frame: From date of randomization till 30 days safety fup, assessed up to approximately 75 months

  • Number of participants with dose adjustments

    The number of participants with dose adjustments (reductions, interruption, or permanent discontinuation) will be summarized by treatment arm.

    Time frame: From date of randomization till 30 days safety fup, assessed up to approximately 75 months

  • Duration of exposure to study treatment

    The duration of exposure in weeks to study treatment and for each study treatment component (JSB462, abiraterone and enzalutamide) will be summarized for each study treatment component by means of descriptive statistics using the SAS.

    Time frame: From date of randomization till 30 days safety fup, assessed up to approximately 75 months

Secondary

  • Radiographic Progression Free Survival (rPFS)

    Time frame: From date of randomization until date of radiographic progression or date of death from any cause, whichever comes first, assessed up to approximately 83 months

  • Overall Survival (OS)

    Time frame: From date of randomization until date of death from any cause, assessed up to approximately 83 months

  • Incidence rate of adverse events (AEs)

    Time frame: From date of randomization till 30 days safety fup, assessed up to approximately 83 months

  • Overall Response Rate (ORR)

    Time frame: From date of randomization until date of progression or date of death from any cause, whichever come first, assessed up to approximately 83 months

  • Disease Control Rate (DCR)

    Time frame: From date of randomization until date of progression or date of death from any cause, whichever come first, assessed up to approximately 83 months

  • Duration of Response (DOR)

    Time frame: From date of randomization until date of progression or date of death from any cause, whichever come first, assessed up to approximately 83 months

  • Time to Response (TTR)

    Time frame: From date of randomization until date of first documented Complete Response (CR) or Partial Response (PR), assessed up to approximately 83 months

  • Time to soft tissue progression (TTSTP)

    Time frame: From date of randomization until date of soft tissue radiographic progression or date of death from any cause, whichever comes first, assessed up to approximately 83 months

  • Prostate Specific Antigen 30 (PSA30) Rate

    Time frame: From date of randomization till 30 days safety fup, assessed up to approximately 75 months

  • Prostate Specific Antigen 50 (PSA50) Rate

    Time frame: From date of randomization till 30 days safety fup, assessed up to approximately 75 months

  • Prostate Specific Antigen 0 (PSA0) Rate

    Time frame: From date of randomization till 30 days safety fup, assessed up to approximately 75 months

  • Duration of biochemical response (DBR)

    Time frame: From date of date of first PSA50 response until date of PSA progression or death from any cause, assessed up to approximately 83 months

  • Time to first symptomatic skeletal event (TTSSE)

    Time frame: From date of randomization till EOT or death, whichever happens first, assessed up to approximately 83 months

  • Plasma concentrations of JSB462 and plasma concentrations of its metabolite ARV-767

    Time frame: Day 1 of Cycles 1 and 2: Pre-dose/0h and Post-dose 4h +/- 1h. Day 1 of Cycles 3 to 8: Pre-dose/0h. End of Treatment Visit (EOT): Anytime. 1 cycle = 28 days.

  • Patient Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)

    Time frame: From randomization up till 30 day safety Follow-up, assessed up to approximately 83 months

Eligibility criteria

Sex: MaleAge: 18 Years and olderHealthy volunteers: No
Key Inclusion Criteria: * An Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) ≤2 * Histologically confirmed adenocarcinoma of the prostate. Participants with mixed histology (neuroendocrine) are not eligible * High-volume mHSPC, defined by the presence of ≥1 metastatic visceral non-nodal lesion and/or ≥4 metastatic bone lesions (with at least one lesion outside the vertebral column and/or pelvis) in imaging exams (CT/MRI or bone scan) according to local radiology assessment by the investigator obtained ≤28 days prior to randomization * Participants must have a castrate level of serum/plasma testosterone (\<50 ng/dL or \<1.7 nmol/L). Ongoing ADT (as defined by prior orchiectomy and/or ongoing GnRH analog/antagonist) for ≤90 days is allowed prior to randomization, provided that PSA zero (PSA level \<0.2 ng/ml according to local laboratory as assessed by the investigator) is not achieved prior to randomization. Key Exclusion Criteria: * Prior exposure to a second generation ARPI (such as enzalutamide/darolutamide/apalutamide and/or abiraterone) for the treatment of advanced/metastatic disease is not allowed. Prior exposure to ARPI, to taxane chemotherapy (up to 6 cycles) or to RLT in the context of (neo)adjuvant treatment for localized prostate cancer is allowed, if the last dose of this treatment was administered \>12 months from randomization. Prior use of a first generation ARPI (such as bicalutamide) in the context of ADT initiation with a GnRH analog is allowed, provided the first generation ARPI was administered for ≤14 days and last dose was administered ≥7 days from randomization. * Participants with biochemical recurrence only or those without evidence of metastatic disease by radiological imaging (CT/MRI or bone scan) are not eligible Other inclusion/exclusion criteria may apply.

Study locations (21)

University of California San Diego - Moores Cancer Center

La Jolla, California, 92093-0658

Recruiting
Rana McKay · Principal Investigator

Saint Johns Cancer Institute

Santa Monica, California, 90404

Recruiting
Przemyslaw Twardowski · Principal Investigator

Rocky Mountain Cancer Centers

Denver, Colorado, 80218

Recruiting
Manojkumar Bupathi · Principal Investigator

Yale Cancer Center

New Haven, Connecticut, 06520

Recruiting
Lindsey Spohn · Contact
Daniel P Petrylak · Principal Investigator

Advanced Urology Ins Daytona Beach

Daytona Beach, Florida, 32114

Recruiting
Sara Esposito · Contact
Samuel Lawindy · Principal Investigator

Emory University School of Medicine-Winship Cancer Institute

Atlanta, Georgia, 30322

Recruiting
Wilena Session · Contact
Shahid Sattar Ahmed · Principal Investigator

Associated Urological Specialists

Chicago Ridge, Illinois, 60415

Recruiting
Daniel Canning · Contact
Aaron Berger · Principal Investigator

American Oncology Partners PA Center for Cancer and Blood Disorders

Bethesda, Maryland, 20817

Recruiting
Jasmine Scott · Contact
Garrett Diltz · Principal Investigator

Mass General Hospital

Boston, Massachusetts, 02114

Recruiting
Manda Ngin · Contact
Xin Gao · Principal Investigator

Michigan Institute of Urology

West Bloomfield, Michigan, 48322

Recruiting
Xiaobei Zhu · Contact
Jason Hafron · Principal Investigator

XCancer Omaha LLC

Omaha, Nebraska, 68130

Recruiting
Tony Romero · Contact
Luke Nordquist · Principal Investigator

Perlmutter Cancer Centre

New York, New York, 10016

Recruiting
Maelia Barry · Contact
Andrew Laccetti · Principal Investigator

Associated Med Professionals of NY

Syracuse, New York, 13210

Recruiting
Brianna Taylor · Contact
Christopher Pieczonka · Principal Investigator

Montefiore Medical Center

The Bronx, New York, 10467

Recruiting
Tahrima Chowdhury · Contact
Benjamin A Gartrell · Principal Investigator

MidLantic Urology

Bala-Cynwyd, Pennsylvania, 19004

Recruiting
Casey Evers · Contact
Laurence Belkoff · Principal Investigator

Fox Chase Cancer Center

Philadelphia, Pennsylvania, 19111

Recruiting
Courtney Lambert · Contact
Daniel Geynisman · Principal Investigator

Carolina Urologic Research Center

Myrtle Beach, South Carolina, 29572

Recruiting
Kim Dannelly · Contact
Neal D Shore · Principal Investigator

Tennessee Oncology

Nashville, Tennessee, 37203

Recruiting
Meghan Mc Guire · Contact
Benjamin Garmezy · Principal Investigator

Urology San Antonio

San Antonio, Texas, 78229

Recruiting
Stefanie Galvan · Contact
Jose De La Cerda · Principal Investigator

Virginia Oncology Associates

Norfolk, Virginia, 23502

Recruiting
Mark Fleming · Principal Investigator

Fred Hutch Cancer Research

Seattle, Washington, 98109

Recruiting
Iris Miyagi Rivera · Contact
Michael Schweizer · Principal Investigator